Search Results - "Zinner, Ralph G"

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors by Janku, Filip, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Falchook, Gerald S., Tsimberidou, Apostolia M., Stepanek, Vanda M., Moulder, Stacy L., Lee, J. Jack, Luthra, Rajyalakshmi, Zinner, Ralph G., Broaddus, Russell R., Wheler, Jennifer J., Kurzrock, Razelle

“…Despite a wealth of preclinical studies, it is unclear whether PIK3CA or phosphatase and tensin homolog (PTEN) gene aberrations are actionable in the clinical…”
Get full text

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer by Zinner, Ralph G, Obasaju, Coleman K, Spigel, David R, Weaver, Robert W, Beck, J Thaddeus, Waterhouse, David M, Modiano, Manuel R, Hrinczenko, Borys, Nikolinakos, Petros G, Liu, Jingyi, Koustenis, Andrew G, Winfree, Katherine B, Melemed, Symantha A, Guba, Susan C, Ortuzar, Waldo I, Desaiah, Durisala, Treat, Joseph A, Govindan, Ramaswamy, Ross, Helen J

“…PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by…”
Get more information

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic by Jardim, Denis L F, Tang, Chad, Gagliato, Debora De Melo, Falchook, Gerald S, Hess, Kenneth, Janku, Filip, Fu, Siqing, Wheler, Jennifer J, Zinner, Ralph G, Naing, Aung, Tsimberidou, Apostolia M, Holla, Vijaykumar, Li, Marylin M, Roy-Chowdhuri, Sinchita, Luthra, Raja, Salgia, Ravi, Kurzrock, Razelle, Meric-Bernstam, Funda, Hong, David S

“…This study aimed to assess MET amplification among different cancers, association with clinical factors and genetic aberrations and targeted therapy response…”
Get full text

Lung Cancer in the Older Patient by Barta, Julie A., MD, Zinner, Ralph G., MD, Unger, Michael, MD

“…Cancers of the lung and bronchus are the leading cause of cancer deaths in men and women in the United States, and two-thirds of new lung cancer cases are…”
Get full text

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426 by ADJEI, Alex A, MANDREKAR, Sumithra J, ZINNER, Ralph G, DY, Grace K, MOLINA, Julian R, ADJEI, Araba A, GANDARA, David R, ALLEN ZIEGLER, Katie L, STELLA, Philip J, ROWLAND, Kendrith M, SCHILD, Steven E

“…To evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non-small-cell lung cancer…”
Get full text

Fingerprinting the circulating repertoire of antibodies from cancer patients by Arap, Wadih, Mintz, Paul J, Kim, Jeri, Do, Kim-Anh, Wang, Xuemei, Zinner, Ralph G, Cristofanilli, Massimo, Arap, Marco A, Hong, Waun Ki, Troncoso, Patricia, Logothetis, Christopher J, Pasqualini, Renata

“…Recognition of molecular diversity in disease is required for the development of targeted therapies. We have developed a screening method based on phage…”
Get full text

Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells by Zinner, Ralph G, Barrett, Brittany L, Popova, Elmira, Damien, Paul, Volgin, Andrei Y, Gelovani, Juri G, Lotan, Reuben, Tran, Hai T, Pisano, Claudio, Mills, Gordon B, Mao, Li, Hong, Waun K, Lippman, Scott M, Miller, John H

“…The standard treatment for most advanced cancers is multidrug therapy. Unfortunately, combinations in the clinic often do not perform as predicted. Therefore,…”
Get full text

Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer by Nemunaitis, John, Eiseman, Irene, Cunningham, Casey, Senzer, Neil, Williams, Adrienne, Lenehan, Peter F, Olson, Stephen C, Bycott, Paul, Schlicht, Michael, Zentgraff, Rebecca, Shin, Dong M, Zinner, Ralph G

“…Purpose: To determine the tolerability and pharmacokinetics of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, administered over 14 consecutive days of a…”
Get full text

Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer by ZINNER, Ralph G, NEMUNAITIS, John, EISEMAN, Irene, SHIN, Hyung Ju C, OLSON, Stephen C, CHRISTENSEN, James, XIN HUANG, LENEHAN, Peter F, DONATO, Nicholas J, SHIN, Dong M

“…Purpose: To determine the tolerability and pharmacokinetics of CI-1033 given daily for 7 days of a 21-day cycle. Tumor response and changes in erbB receptor…”
Get full text

Dose Escalation of Gemcitabine Is Possible With Concurrent Chest Three-Dimensional Rather Than Two-Dimensional Radiotherapy: A Phase I Trial in Patients With Stage III Non–Small-Cell Lung Cancer by Zinner, Ralph G., M.D, Komaki, Ritsuko, M.D, Cox, James D., M.D, Glisson, Bonnie S., M.D, Pisters, Katherine M.W., M.D, Herbst, Roy S., M.D., Ph.D, Kies, Merril, M.D, Liao, Zhongxing, M.D, Hong, Waun K., M.D, Fossella, Frank V., M.D

“…Purpose To determine in a Phase I study the maximum tolerated dose of weekly gemcitabine concurrent with radiotherapy in locally advanced non–small-cell lung…”
Get full text

S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer by Shen, Hua, Wang, Gao-Chan, Li, Xiang, Ge, Xin, Wang, Meng, Shi, Zhu-Mei, Bhardwaj, Vikas, Wang, Zi-Xuan, Zinner, Ralph G., Peiper, Stephen C., Aplin, Andrew E., Jiang, Bing-Hua, He, Jun

“…The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In…”
Get full text

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System by Janku, Filip, Huang, Helen J, Claes, Bart, Falchook, Gerald S, Fu, Siqing, Hong, David, Ramzanali, Nishma M, Nitti, Giovanni, Cabrilo, Goran, Tsimberidou, Apostolia M, Naing, Aung, Piha-Paul, Sarina A, Wheler, Jennifer J, Karp, Daniel D, Holley, Veronica R, Zinner, Ralph G, Subbiah, Vivek, Luthra, Rajyalakshmi, Kopetz, Scott, Overman, Michael J, Kee, Bryan K, Patel, Sapna, Devogelaere, Benoit, Sablon, Erwin, Maertens, Geert, Mills, Gordon B, Kurzrock, Razelle, Meric-Bernstam, Funda

“…Cell-free (cf) DNA from plasma offers an easily obtainable material for BRAF mutation analysis for diagnostics and response monitoring. In this study,…”
Get full text

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early‐phase oncology clinical trials by George, Goldy C., Iwuanyanwu, Eucharia C., Anderson, Karen O., Yusuf, Alizeh, Zinner, Ralph G., Piha‐Paul, Sarina A., Tsimberidou, Apostolia M., Naing, Aung, Fu, Siqing, Janku, Filip, Subbiah, Vivek, Cleeland, Charles S., Mendoza, Tito R., Hong, David S.

“…BACKGROUND Limited data exist about sleep quality for patients with advanced cancer in phase 1 clinical trials. Poor sleep quality is often not captured as an…”
Get full text

Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers by Janku, Filip, Sakamuri, Divya, Kato, Shumei, Huang, Helen J., Call, S. Greg, Naing, Aung, Holley, Veronica R., Patel, Sapna P., Amaria, Rodabe N., Falchook, Gerald S., Piha‐Paul, Sarina A., Zinner, Ralph G., Tsimberidou, Apostolia M., Hong, David S., Meric‐Bernstam, Funda

“…Background BRAF inhibitors are effective in melanoma and other cancers with BRAF mutations; however, patients ultimately develop therapeutic resistance through…”
Get full text

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies by Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M, Fu, Siqing, Naing, Aung, Falchook, Gerald S, Hong, David S, Holley, Veronica R, Cabrilo, Goran, Wheler, Jennifer J, Piha-Paul, Sarina A, Zinner, Ralph G, Bedikian, Agop Y, Overman, Michael J, Kee, Bryan K, Kim, Kevin B, Kopetz, E Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle

“…Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable source of biologic material for mutation analysis. Plasma samples from 157…”
Get full text

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy by Park, Haeseong, Garrido-Laguna, Ignacio, Naing, Aung, Fu, Siqing, Falchook, Gerald S, Piha-Paul, Sarina A, Wheler, Jennifer J, Hong, David S, Tsimberidou, Apostolia M, Subbiah, Vivek, Zinner, Ralph G, Kaseb, Ahmed O, Patel, Shreyaskumar, Fanale, Michelle A, Velez-Bravo, Vivianne M, Meric-Bernstam, Funda, Kurzrock, Razelle, Janku, Filip

“…Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We…”
Get full text

Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky by Brainson, Christine F., Huang, Bin, Chen, Quan, McLouth, Laurie E., He, Chunyan, Hao, Zhonglin, Arnold, Susanne M., Zinner, Ralph G., Mullett, Timothy W., Bocklage, Therese J., Orren, David K., Villano, John L., Durbin, Eric B.

“…•Kentucky has significantly higher proportions of small cell and squamous cell carcinomas•Appalachian females have 3.5-fold higher incidence rates of small…”
Get full text

Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents by Ganesan, Prasanth, Moulder, Stacy, Lee, J Jack, Janku, Filip, Valero, Vicente, Zinner, Ralph G, Naing, Aung, Fu, Siqing, Tsimberidou, Apostolia M, Hong, David, Stephen, Bettzy, Stephens, Philip, Yelensky, Roman, Meric-Bernstam, Funda, Kurzrock, Razelle, Wheler, Jennifer J

“…Patients with metastatic triple-negative breast cancer (TNBC) have poor treatment outcomes. We reviewed the electronic records of consecutive patients with…”
Get full text

Parametric dose standardization for optimizing two-agent combinations in a phase I-II trial with ordinal outcomes by Thall, Peter F., Nguyen, Hoang Q., Zinner, Ralph G.

“…A Bayesian model and design are described for a phase I-II trial to optimize jointly the doses of a targeted agent and a chemotherapy agent for solid tumours…”
Get full text

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care by Patel, Jyoti D., Paz-Ares, Luis, Zinner, Ralph G., Barlesi, Fabrice, Koustenis, Andrew G., Obasaju, Coleman K.

“…Although lung cancer prognosis remains poor for most patients, treatments developed in the past 2 decades have extended survival for many. For those with…”
Get full text